Era of direct acting anti-viral agents for the treatment of hepatitis C.

Authors

Monjur Ahmed, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

10-1-2018

Comments

This article has been peer reviewed. It is the author’s final published version in World Journal of Hepatology, Volume 27, Issue 10, October 2018, Pages 670-684.

The published version is available at https://doi.org/10.4254/wjh.v10.i10.670. Copyright © Ahmed

Abstract

Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone. Now we have stepped into the era of direct acting anti-viral agents (DAAs) against hepatitis C virus. Treatment of hepatitis C is now extremely effective, tolerable and requires a short duration of intake of oral agents. Less monitoring is required with the current therapy and drug-drug interactions are less than the previous regimen. The current treatment options of chronic hepatitis C with various DAAs are discussed in this article.

Recommended Citation

Ahmed, Monjur, "Era of direct acting anti-viral agents for the treatment of hepatitis C." (2018). Division of Gastroenterology and Hepatology Faculty Papers. Paper 52.
https://jdc.jefferson.edu/gastro_hepfp/52

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

PubMed ID

30386460

Language

English